Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2003

View Archived Issues

FluINsure shows positive results in influenza challenge study

Twice-daily schedule suggested for fampridine-SR in patients with chronic SCI

Astex achieves milestone in Alzheimer's drug discovery collaboration

CAT and Genzyme strengthen drug development collaboration

DepoMed acquires exclusive rights to novel gabapentin formulation

Phase IIa study initiated with SPI-8811 for cystic fibrosis

Alnylam enters RNAi-based therapy collaboration with Stanford University

Pivotal trial for Hunter's syndrome begins dosing

New formulation of Singulair available for young children with asthma

FDA grants satraplatin fast track designation

New antiangiogenic agents and their use patented by EntreMed

Takeda presents new GnRH antagonists for cancer, prostatic hypertrophy, etc.

Dainippon scientists prepare and test novel glucagon antagonists

New antifungal agents in early development at Daiichi

Novel agents for urinary incontinence described by Mochida and Asahi Glass

New CDK inhibitors in BMS development pipeline

Phase IIIa study of Neutralase halted

FDA accepts filing for DepoMorphine

Lumiracoxib approved by the MHRA for osteoarthritis and other indications

New CCR3 antagonist with oral activity in animal model of atopic dermatitis

3DP presents new orally active thrombin inhibitors at ACS meeting

Development of potent, selective cPLA2alpha inhibitors as antiinflammatory/analgesic agents

BMS discovers selective, orally active TACE inhibitors with antiinflammatory activity

RPR-749 is safe and lowers FFA levels in first human trial

Influenza virus neuraminidase inhibitor R-118958 and its active metabolite characterized by Sankyo

Good safety and PK profile emerges for CC-8490 in healthy volunteers

Tolvaptan preserves renal function in patients with congestive heart failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...